Evoke Pharma Inc (EVOK)
4.41
-0.09
(-2.00%)
USD |
NASDAQ |
Nov 22, 14:37
Evoke Pharma Gross Profit Margin (Quarterly): 96.08% for Sept. 30, 2024
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 96.08% |
| June 30, 2024 | 98.37% |
| March 31, 2024 | 94.67% |
| December 31, 2023 | 96.48% |
| September 30, 2023 | 97.77% |
| June 30, 2023 | 94.93% |
| March 31, 2023 | 93.76% |
| December 31, 2022 | 76.13% |
| Date | Value |
|---|---|
| September 30, 2022 | 89.21% |
| June 30, 2022 | 85.32% |
| March 31, 2022 | 94.56% |
| December 31, 2021 | 62.09% |
| September 30, 2021 | 93.72% |
| June 30, 2021 | 71.16% |
| March 31, 2021 | 28.39% |
| December 31, 2020 | -276.7% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
-276.7%
Minimum
Dec 2020
98.37%
Maximum
Jun 2024
62.25%
Average
93.74%
Median
Gross Profit Margin (Quarterly) Benchmarks
| Repligen Corp | 50.03% |
| Eli Lilly and Co | 81.02% |
| MEI Pharma Inc | -- |
| Revance Therapeutics Inc | 70.55% |
| NovaBay Pharmaceuticals Inc | 65.26% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -433.1% |
| Return on Assets | -57.27% |
| Return on Invested Capital | -95.76% |
| Profit Margin (Quarterly) | -49.45% |
| Operating Margin (Quarterly) | -48.44% |